Background Serum creatinine is not a satisfactory marker of glomerular filtration rate (GFR) in patients with spinal cord injury (SCI) who have varying degrees of muscle atrophy. In contrast to serum creatinine, serum cystatin C, a 13-kDa protein, is not affected by muscle mass and is therefore potentially a useful marker of GFR in patients with SCI. In addition, cystatin C is not dependent on sex or age and is not secreted by the renal tubule.
Introduction
The assessment of renal function is important in the management of patients with spinal cord injury (SCI) and neurogenic bladder dysfunction. The most widely used measure of glomerular ¢ltration rate (GFR) is the serial measurement of the serum creatinine concentration. The major disadvantage of serum creatinine in SCI is that creatinine production is dependent on muscle mass, which is signi¢cantly decreased in patients with SCI as a result of the di¡use muscle atrophy that accompanies muscle degeneration. Reliance on serum creatinine may underestimate GFR and an accurate measure of GFR is essential in determining safe doses of drugs such as aminoglycosides. 1 Mcdiarmid et al. 2 found serum creatinine to be an insensitive marker of GFR and the creatinine clearance calculated by the Cockcroft-Gault formula to overestimate GFR. There was a better correlation of the 24-h endogenous creatinine clearance with the clearance of technetium-labelled diethylenetriaminepentaacetic acid ([ 99m Tc]DTPA) which is a generally accepted accurate measure of GFR. However, estimation of creatinine clearance is not convenient as this requires prolonged collection of urine. A simple serum analyte would be more practical and useful.
Serum cystatin C, a low molecular weight protein (MW 13350) has been advocated as a measure of GFR 3,4 and of early renal impairment. 5 Serum cystatin 364 &2003 The Association of Clinical Biochemists
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C concentrations have been shown to be closely related to the clearance of inulin, [ 51 Cr]EDTA and [ 99m Tc]DTPA and iohexol (reviewed in reference 4). The reference range for cystatin C is also similar for men and women 6 and is independent of age, height and muscle mass in children. 7 A single reference range could be used between the ages of 1 and 50 years, 4 with the cystatin C rising in those over 50 years as the GFR falls in the elderly. 8 There are now several commercially available assays for cystatin C.
We investigated the use of cystatin C as a measure of renal function in patients with SCI using a commercially available nephelometric method. This study was performed by measuring cystatin C samples routinely received in the laboratory for serum creatinine and/or creatinine clearance.
Materials and methods

Patients
SCI patients
Patients in the spinal cord service at Austin Health have their serum creatinine, urea and electrolytes measured at intervals for management. They also have their creatinine clearance assessed on occasion. Serum cystatin C was measured on 110 samples routinely received in the laboratory from 64 patients: 53 men [mean (standard deviation, SD) age 47.3 (16.3) years, range 19-80 years] and 11 women [mean (SD) age 56.7 (14.3) years, range 33-86 years]. Twentyeight of these patients were paraplegic and 38 quadriplegic. The causes of the SCI were: motor car/bicycle accident (31); fall (12); other accident (nine); disease of the spinal cord (12). Twenty-two per cent of the SCI patients had had their paraplegia/quadriplegia for longer than 20 years, and 36% of these patients had had paraplegia/quadriplegia for less than 6 months. We compared serum cystatin C and serum creatinine with the creatinine clearance when available (27 patients: 20 men and seven women).
Non-SCI patients
We measured cystatin C in serum samples received for creatinine clearance measurement in 57 non-SCI patients (26 men and 31 women).
Normal subjects
Cystatin C results from a reference range study involving 81 normal laboratory sta¡ (24 men and 57 women) were included in the analysis.
Methods
Serum creatinine was measured by the Ja¡e¨reaction on an Hitachi 747 or Hitachi 917 instrument (Roche Diagnostics, Basel, Switzerland), using Roche reagent according to the manufacturer's instructions. Standardization was by CFAS calibrator supplied by Roche for Hitachi automated systems. Liquichek 1 and 11 (Bio-Rad Laboratories, Hercules, CA, USA) were used as quality control serum samples. The coe¤cient of variation (CV) was 3¢3% at 0¢671 mmol/ L on the Hitachi 747 and 2¢3% at 0¢671 mmol/ L on the Hitachi 917 (nˆ30 in each case).
Urine creatinine was measured by the Ja¡e reaction on an Hitachi 917 using Roche reagent according to the manufacturer's instructions. Standardization was by in-house aqueous calibrator. Liquichek Urine Control (Bio-Rad Laboratories) was used as quality control material. The CV of the assay was 4¢2% at a urine level of 8¢5 mmol/ L (nˆ30).
Cystatin C was measured on a BN ProSpec (Dade Behring, Marburg, Germany) using an automated particle-enhanced nephelometric immunoassay kit manufactured by Dade Behring. A six-point calibration was performed by the instrument, quality control material also being supplied in the kit. The intra-assay CV was 1¢48% at a level of 1¢35 mg/L (nˆ20); the inter-assay CV was 7¢4% at a level of 1¢63 mg/L (nˆ19).
Results
There was a signi¢cant correlation of both 1/cystatin C and 1/creatinine with creatinine clearance in non-SCI patients for all subgroups. By contrast, the SCI group as a whole, or the male SCI patients, had a better correlation of 1/cystatin C with creatinine clearance than 1/creatinine with creatinine clearance (see Table 1 and Fig. 1 ). Only seven women were included in the SCI group, which showed a statistically poor correlation with the reciprocal of cystatin C (rˆ0¢46, Pˆ0 ¢3) and a better correlation with 1/creatinine (rˆ0¢86, P50 ¢01). The interpretation of this relationship is limited by the very small number of female SCI patients.
The degree of muscle atrophy is shown by the ¢nding that the mean (SD) serum creatinine of the 53 male SCI patients 0¢0563 (0¢025) mmol/ L was signi¢cantly lower (P50¢00001) than that of the 24 male normal subjects [0¢0868 (0¢021) mmol/ L], even though some of the SCI patients had renal impairment. In contrast, the cystatin C of the 53 male SCI patients [0 ¢ 967 (0 ¢ 387) mg/L] was signi¢cantly higher (P50.001) than the 24 normal male subjects [0 ¢ 761 (0¢188) mg/L), re£ecting the renal impairment found in some members of this group. Table 2 shows the relationship of serum cystatin C and serum creatinine for the di¡erent groups of patients according to sex. Figure 2 shows a comparison of serum creatinine versus cystatin C in the men from all three groups: normal subjects, non-SCI patients and SCI patients. This showed that SCI patients have signi¢cantly lower creatinine values for the same cystatin C value when compared to non-SCI and normal individuals. This ¢nding relates to the severe degree of muscle atrophy in the SCI patients. This is also shown in Fig. 1 , where, for the same creatinine clearance values, the reciprocals of the serum cystatin C are similar among male SCI patients and male non-SCI patients. However, the reciprocals of the serum creatinine are very much higher for male SCI patients than for the male non-SCI patients. This was the same for the seven female patients in spite of the excellent correlation of creatinine clearance with serum creatinine mentioned above. The reason again is the lower serum creatinine for a given creatinine clearance in the SCI patients because of their lower muscle mass, giving a higher reciprocal value of serum creatinine. Table 1 . The plots also show that the cystatin C concentrations are numerically similar for a given creatinine clearance in the two groups of patients. (b) Plots of creatinine clearance versus 1/creatinine for 20 male SCI patients (.) compared with 26 non-SCI patients (^). Correlation data are given in Table 1 .
Discussion
Cystatin C has several attributes that make it an excellent marker of GFR. Its production is stable, being produced by most nucleated cells. 1 Although variation in production has been shown in vitro, there have been no studies that demonstrate any major in£uence of exogenous agents, infection or malignancy on the serum concentration of cystatin C. 9 Owing to its small size, it is freely ¢ltered by the glomerulus. The ¢ltered material is taken up and catabolized by the proximal tubular cells and there is negligible peritubular uptake. 3 The suitability of cystatin C as a measure of GFR has been shown by many workers comparing it with accepted gold standards for GFR (for reviews see references 4 and 9). The most important attribute of cystatin C with respect to our group of patients with SCI is that the levels are not a¡ected by muscle mass. 10 Men, women and children share the same reference range, 6,7 unlike serum creatinine. Creatinine clearance is not a¡ected by muscle mass. However, creatinine is secreted by the tubules and will overestimate the GFR; it also requires collection of urine for 24 h. Serum creatinine, although convenient and cheap, is not suitable for patients with SCI since they have varying degrees of muscle atrophy. This important issue is con¢rmed in the present study.
Our study is limited by the absence of a gold standard (e.g. inulin clearance, [ 99m Tc]DTPA) measure of GFR. However, using creatinine clearance as our surrogate measure of GFR, Table 1shows that, for male non-SCI patients, the correlation of creatinine clearance with the reciprocal of serum creatinine was marginally better than with the reciprocal of serum cystatin C. By contrast, the correlation of creatinine clearance with the reciprocal serum creatinine was markedly inferior to the correlation with the reciprocal of cystatin C, for male SCI patients. This could be explained by the variable muscle atrophy in SCI patients contributing to the variation in serum creatinine concentration. We also con¢rm, as is known, 1,2 that the absolute level of serum creatinine is a poor marker of renal impairment in SCI patients because of the varying degree and range of muscle atrophy in paraplegic and quadriplegic patients. The absolute value of cystatin C would be a better marker.
The disadvantages of cystatin C at present are: (a) lack of an international standard, as yet; (b) the high cost of the assay in comparison with serum creatinine; and (c) the lack (because it is still not widely used) of external quality assessment. These problems may be solved in the future if the assay comes into wider use.
In conclusion, serum cystatin C re£ects renal impairment in patients with SCI, irrespective of the degree of muscle atrophy, and shows promise as a measure of renal function in this group of patients. Further studies using [ 99m Tc]DTPA are required.
